Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis

Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis

10.1007/s12325-020-01395-x

Saved in:
Bibliographic Details
Main Authors: Huang, Shang-Yi, Yoon, Sung-Soo, Shimizu, Kazuyuki, Chng, Wee Joo, Chang, Cheng-Shyong, Wong, Raymond Siu-Ming, Gao, Seasea, Wang, Yang, Gordon, Steve W, Glennane, Anthony, Min, Chang-Ki
Other Authors: DEAN'S OFFICE (MEDICINE)
Format: Article
Language:English
Published: SPRINGER 2022
Subjects:
Science & Technology
Life Sciences & Biomedicine
Medicine, Research & Experimental
Pharmacology & Pharmacy
Research & Experimental Medicine
Asian patients
Denosumab
Multiple myeloma
Skeletal-related event
Zoledronic acid
SKELETAL-RELATED EVENTS
PLACEBO-CONTROLLED TRIAL
POSTMENOPAUSAL WOMEN
PREVENTION
CANCER
Online Access:https://scholarbank.nus.edu.sg/handle/10635/229004
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
Language: English

Internet

https://scholarbank.nus.edu.sg/handle/10635/229004

Similar Items